MIM
SNNA

MetLife Investment Management’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

MetLife Investment Management’s Portfolio SNNA Stock Details SNNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-7,806
Closed -$147K – 2253
2018
Q1 		$147K Buy
+7,806
New +$136K ﹤0.01% 2049

Other funds holding SNNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MetLife Investment Management's SNNA Position: Q2 2018 in Review

MetLife Investment Management sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q2 2018, closing a stake of 7,806 shares — an estimated $147K sold.

MetLife Investment Management first reported a position in SNNA in Q1 2018 and held it in 1 quarter. The position peaked at $147K in Q1 2018. 53 funds tracked by Wall St. Rank hold SNNA as of Q2 2018.

  • MetLife Investment Management reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
  • MetLife Investment Management sold 7,806 Sienna Biopharmaceuticals, Inc. shares in Q2 2018, an estimated $147K.
  • MetLife Investment Management first reported a position in Sienna Biopharmaceuticals, Inc. in Q1 2018 and held it in 1 quarter.
  • MetLife Investment Management's Sienna Biopharmaceuticals, Inc. position peaked at $147K in Q1 2018.
  • 53 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q2 2018.

Based on MetLife Investment Management's 13F filing for Q2 2018, filed 15 Aug 2018.